Celadon Pharmaceuticals PLC
LSE:CEL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Exponent Inc
NASDAQ:EXPO
|
US |
|
A
|
Axita Cotton Ltd
NSE:AXITA
|
IN |
|
Beachbody Company Inc
NYSE:BODI
|
US |
Celadon Pharmaceuticals PLC
Total Assets
Celadon Pharmaceuticals PLC
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Celadon Pharmaceuticals PLC
LSE:CEL
|
Total Assets
£2.2B
|
CAGR 3-Years
535%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Croda International PLC
LSE:CRDA
|
Total Assets
£3.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Science in Sport PLC
LSE:SIS
|
Total Assets
£66.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Chill Brands Group PLC
LSE:CHLL
|
Total Assets
£2.1m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Venture Life Group PLC
LSE:VLG
|
Total Assets
£124.9m
|
CAGR 3-Years
6%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
|
Provexis PLC
LSE:PXS
|
Total Assets
£841.8k
|
CAGR 3-Years
-6%
|
CAGR 5-Years
16%
|
CAGR 10-Years
7%
|
|
Celadon Pharmaceuticals PLC
Glance View
Summerway Capital Plc engages in acquiring companies or businesses that has the potential for strategic, operational, and performance improvement. The firm is engaged in research, cultivation, manufacturing and supply of cannabinoid-based medicines. The firm is focused on growing indoor hydroponic cannabis initially for the chronic pain market. The company is also focused on improving the quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based medicines for other conditions such as autism. The firm's facility comprises an indoor, closed-loop hydroponic system to ensure cannabis plants are cultivated under a highly specific climate, light and with irrigation control. The firm's subsidiary, LVL Health is a medical cannabis clinic for chronic pain that owns a medicines and healthcare products regulatory agency (MHRA) conditionally approved cannabis trial using cannabis-based medicinal products to treat chronic pain in the United Kingdom.
See Also
What is Celadon Pharmaceuticals PLC's Total Assets?
Total Assets
2.2B
GBP
Based on the financial report for Dec 31, 2024, Celadon Pharmaceuticals PLC's Total Assets amounts to 2.2B GBP.
What is Celadon Pharmaceuticals PLC's Total Assets growth rate?
Total Assets CAGR 3Y
535%
Over the last year, the Total Assets growth was 1%. The average annual Total Assets growth rates for Celadon Pharmaceuticals PLC have been 535% over the past three years .
